Sugi Predict

Sugi Predict / Compounds / SCHEMBL907424

SCHEMBL907424

SCHEMBL907424

COc1cc2c(Nc3ccc(Br)c(Cl)c3)ncnc2cc1OC(=O)C(F)(F)F

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 9/20 0.61
▸ KDR P35968 14/20 0.61
▸ ERBB2 P04626 13/20 0.61
▸ EPHB4 P54760 10/20 0.61
▸ AURKA O14965 1/20 0.61
▸ INSR P06213 1/20 0.61
▸ FBP1 P09467 1/20 0.61
▸ PDGFRB P09619 1/20 0.61
▸ FLT4 P35916 1/20 0.61
▸ CLK1 P49759 1/20 0.61
▸ TEK Q02763 1/20 0.61
▸ AURKB Q96GD4 1/20 0.61
▸ EPHA2 P29317 9/20 0.60
▸ ABCB1 P08183 1/20 0.58
▸ JAK3 P52333 1/20 0.58
▸ ABCG2 Q9UNQ0 1/20 0.58
▸ RET P07949 1/20 0.58
▸ KIF5B P33176 1/20 0.58
▸ FLT1 P17948 1/20 0.58
▸ HDAC3 O15379 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL906971 0.92 KDR (0.64) EGFRKDRERBB2EPHB4AURKA
SCHEMBL28420973 0.90 EGFR (0.77) EGFRKDRERBB2EPHB4AURKA
SCHEMBL14095961 0.87 EGFR (0.80) EGFRKDRERBB2EPHB4AURKA
SCHEMBL907136 0.85 KDR (0.58) EGFRKDRERBB2EPHB4FLT4
Trifluoroacetic Acid SCHEMBL907422 0.85 KDR (0.58) EGFRKDRERBB2EPHB4AURKA
SCHEMBL907481 0.84 EGFR (0.63) EGFRKDRERBB2EPHB4EPHA2
SCHEMBL907178 0.81 KDR (0.69) EGFRKDRERBB2EPHB4AURKA
SCHEMBL907409 0.80 EGFR (0.76) EGFRKDRERBB2EPHB4FLT4
SCHEMBL22630824 0.79 KDR (0.69) EGFRKDRERBB2EPHB4AURKA
SCHEMBL2089052 0.79 KDR (0.77) EGFRKDRERBB2EPHB4PDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10266518-B2 Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof SYMPHONY EVOLUTION, INC. (US) 2019-04-23 — — US disclosed
EP-1521747-B1 RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE SYMPHONY EVOLUTION INC (US) 2018-09-05 — — EP disclosed
US-20180118724-A1 Receptor-Type Kinase Modulators and Methods of Use SYMPHONY EVOLUTION, INC. (US) 2018-05-03 — — US disclosed
US-9796704-B2 Substituted quinazolines as receptor-type kinase inhibitors SYMPHONY EVOLUTION, INC. (US) 2017-10-24 — — US disclosed
US-9359332-B2 Processes for the preparation of substituted quinazolines SYMPHONY EVOLUTION, INC. (US) 2016-06-07 — — US disclosed
US-20160129032-A1 Receptor-Type Kinase Modulators and Methods of Use SYMPHONY EVOLUTION, INC. (US) 2016-05-12 — — US disclosed
US-9163006-B2 — — 2015-10-20 — — US disclosed
US-20140155418-A1 Receptor-Type Kinase Modulators and Methods of Use SYMPHONY EVOLUTION, INC. (US) 2014-06-05 — — US disclosed
US-8658654-B2 Receptor-type kinase modulators and methods of use SYMPHONY EVOLUTION, INC. (US) 2014-02-25 — — US disclosed
EP-2277867-B1 Compounds, pharmaceutical compositions thereof and their use in treating cancer SYMPHONY EVOLUTION INC (US) 2012-12-05 — — EP disclosed
EP-2280003-A2 Process for preparing receptor-type kinase modulators Symphony Evolution, Inc. (US) 2011-02-02 — — EP disclosed
EP-2277867-A2 Compounds, pharmaceutical compositions thereof and their use in treating cancer Symphony Evolution, Inc. (US) 2011-01-26 — — EP disclosed
US-20090318373-A1 Receptor-type kinase modulators and methods of use KADMON CORPORATION, LLC 2009-12-24 — — US disclosed
US-7576074-B2 Receptor-type kinase modulators and methods of use KADMON CORPORATION, LLC 2009-08-18 — — US disclosed
EP-1521747-A4 RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2006-10-11 — — EP disclosed
US-20060069077-A1 Receptor-type kinase modulators and methods of use KADMON CORPORATION, LLC 2006-03-30 — — US disclosed
EP-1521747-A2 RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2005-04-13 — — EP disclosed
WO-2004006846-A2 RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060069077-A1 Receptor-type kinase modulators and methods of use EGFR, EPHA2, ERBB4 EGFR 1/4885KDR 17/4885ERBB2 5/4885
US-10266518-B2 Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof EGFR, ERBB4, ERBB3 EGFR 1/4885KDR 16/4885ERBB2 6/4885
US-20180118724-A1 Receptor-Type Kinase Modulators and Methods of Use EGFR, EPHA2, ERBB4 EGFR 1/4885KDR 17/4885ERBB2 5/4885
US-20090318373-A1 Receptor-type kinase modulators and methods of use EGFR, EPHA2, ERBB4 EGFR 1/4885KDR 17/4885ERBB2 5/4885
US-20160129032-A1 Receptor-Type Kinase Modulators and Methods of Use EGFR, EPHA2, ERBB4 EGFR 1/4885KDR 17/4885ERBB2 5/4885
US-20140155418-A1 Receptor-Type Kinase Modulators and Methods of Use EGFR, EPHA2, ERBB4 EGFR 1/4885KDR 17/4885ERBB2 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.